Primary liver tumors

Seminars in Surgical Oncology

Volumn 19, Issue 2, 2000, Pages 135-144

  Lau, W Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Age factors; Alpha fetoproteins; Combined antineoplastic agents; Combined modality therapy; Hemorrhage; Hepatectomy; Hepatocellular carcinoma; Hormonal antineoplastic agents; Interferon alpha; Interventional ultrasound; Iodine radioisotopes; Iodized oil; Laparoscopy; Liver cirrhosis; Liver neoplasms; Liver transplantation; Liver surgery; Mass screening; Neoplasm metastasis; Prognosis; Risk factors; Sex factors; Survival rate; Therapeutic embolization; Treatment outcome; Yttrium radioisotopes

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL;

ARTERY CATHETERIZATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GENE THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LIVER TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VOLUMETRY;

EID: 0033777169     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2388(200009)19:2<135::AID-SSU6>3.0.CO;2-A     Document Type: Article

References (104)

1. The history of liver surgery
2. Neoplasms of the liver
3. Epidemiology of hepatocellular carcinoma
4. Epidemiology, risk factors, etiology, premalignant lesions and carcinogenesis
5. Hepatitis B virus: The major etiology of hepatocellular carcinoma
6. Prevalence of antibodies to hepatitis C virus in hepatocellular carcinoma
7. Hepatitis C-associated hepatocellular carcinoma
8. Hepatitis C and hepatocellular carcinoma
9. An analysis of 412 cases of hepatocellular carcinoma at a Western center
10. Hepatitis C and alcohol
11. Hepatocellular carcinoma in alcoholics
12. Primary prevention of hepatocellular carcinoma
13. The importance of a coexistent hepatic rub and bruit
14. Clinical manifestations of hepatoma. A review of 6 years experience at a cancer hospital
15. Hepatocellular carcinoma in Hong Kong: Clinical study on 348 cases
16. Clinical features of hepatocellular carcinoma: Review of 211 patients in Hong Kong
17. A prospective study of upper gastrointestinal hemorrhage in patients with hepatocellular carcinoma
18. Management of bleeding liver tumors in Hong Kong
19. Spontaneous rupture of hepatocellular carcinoma: A review of 172 Japanese cases
20. 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease
21. Subclinical hepatocellular carcinoma: An analysis of 391 patients
22. Obstructive jaundice secondary to hepatocellular carcinoma
23. Paraneoplastic manifestations of hepatocellular carcinoma
24. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. The Liver Cancer Study Group of Japan
25. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases
26. Factors correlated with portal venous invasion by hepatocellular carcinoma: Univariate and multivariate analyses of 232 resected cases without preoperative treatment
27. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications
28. Early detection of hepatocellular carcinoma
29. Hepatocellular carcinoma in Italian patients with cirrhosis
30. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis
31. Presentation and approach to diagnosis
32. Surgical management (including liver transplantation)
33. Management of tumors of the liven Combined use of arteriography and venography in the assessment of resectability, especially in hilar tumors
34. Hepatic intra-arterial lipiodol ultrasound guided biopsy in the management of hepatocellular carcinoma
35. Hepatectomy for hepatocarcinoma on a cirrhotic liver: Decision plans and principles of perioperative resuscitation. Experience with 204 cases
36. Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function
37. Can hepatic failure after surgery for hepatocellular carcinoma in cirrhotic patients be prevented?
38. High preoperative serum alanine transferase levels: Effect on the risk of liver resection in Child grade A cirrhotic patients
39. Perioperative predictors of morbidity following hepatic resection for neoplasm. A multivariate analysis of a single surgeon experience with 105 patients
40. Intraoperative risk factors associated with hepatic resection
41. Transection of the oesophagus for bleeding oesophageal varices
42. Surgery and portal hypertension
43. Liver resection in cirrhosis of the liver
44. Evaluation of 50 consecutive segmental hepatic resections
45. Aminopyrine breath test predicts surgical risk for patients with liver disease
46. A multiple regression equation for prediction of post-hepatectomy liver failure
47. Response of hepatic mitochrondrial redox state to oral glucose load. Redox tolerance test as a new predictor of surgical risk in hepatectomy
48. Improved staging of liver tumors using laparoscopic intraoperative ultrasound
49. Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma
50. Fibrolamella carcinoma: Clinical and pathological features
51. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications
52. Histologic prognostic indicators in hepatocellular carcinoma
53. Clinicopathologic study on clear cell hepatocellular carcinoma
54. Hepatic resection for hepatocellular carcinoma: An audit of 343 patients
55. Hepatic resection for small hepatocellular carcinoma: The Queen Mary Hospital experience
56. Liver resection for hepatocellular carcinoma in the elderly
57. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment
58. Resection of hepatocellular carcinoma with diaphragmatic invasion
59. Improved survival with resection after transcatheter arterial chemoembolisation (TACE) for unresectable hepatocellular carcinoma
60. Is preoperative hepatic arterial chemoembolisation safe and effective for hepatocellular carcinoma?
61. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: Evaluation with analysis of 72 patients
62. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90 yttrium microspheres
63. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
64. Selective percutaneous transhepatic embolisation of the portal vein in preparation for extensive liver resection: The ipsilateral approach
65. Right portal vein embolisation in preparation for major hepatic resection
66. Treatment of hepatocellular carcinoma: A systemic review of randomised controlled trials
67. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma
68. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial
69. Liver transplantation for hepatocellular carcinoma: Clinical results and future aspects
70. Liver transplantation for hepatocellular carcinoma
71. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis
72. Experience of orthotopic liver transplantation and hepatic resection for hepatocellular carcinoma of less than 8 cm in patients with cirrhosis
73. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients
74. Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence
75. Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study
76. Current treatment modalities for hepatocellular carcinoma
77. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: A pilot study in 20 patients
78. Cytoreductive surgery for hepatocellular carcinoma
79. Place of cryosurgery in the treatment of malignant liver tumors
80. Intratumor ethanol injection therapy for solitary minute hepatocellular carcinoma. A study of 37 patients
81. Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection
82. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients
83. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study of 22 patients
84. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma - An impossible meta-analysis?
85. Comments on: Percutaneous hyperthermic distilled water injection therapy (PHDT) for liver cancer
86. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma
87. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment of hepatoma
88. A randomised trial of intrahepatic arterial infusion of 4'-epidoxorubicin with lipiodol versus 4'-epidoxorubicin alone in the treatment of hepatocellular carcinoma
89. A randomised trial of hepatic arterial chemoembolisation in patients with unresectable hepatocellular carcinoma
90. Hepatic arterial embolisation in patients with unresectable hepatocellular carcinoma. A randomised controlled trial
91. A prospective randomised evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolisation
92. A comparison of lipiodol chemoembolisation and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitment du Carcinome Hepatocellulaire
93. Transcatheter arterial embolisation with or without cisplatin in treatment of hepatocellular carcinoma. A randomised controlled study
94. Nonresectional therapies for hepatocellular carcinoma
95. Internal radiation therapy for patients with primary or metastatic hepatic cancer: A review
96. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: A prospective randomised trial
97. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial
98. Patient characteristics that predict response and survival after systemic PIAF chemotherapy for inoperable hepatocellular carcinoma
99. Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study
100. Octreotide in hepatocellular carcinoma
101. Gene therapy for primary and metastatic cancer to the liver
102. Hospice care
103. Hepatic tumours
104. Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers